Texas is currently home to 4888 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer
Recruiting
The main objective of this study is to evaluate the safety and tolerability of xaluritamig monotherapy in adult participants with high-risk biochemical recurrent (BCR) nonmetastatic castration-sensitive prostate cancer (nmCSPC).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Prostate Cancer, High-risk Biochemical Recurrence, High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer, Non-metastatic Castration-sensitive Prostate Cancer
Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)
Recruiting
The purpose of this study is to determine whether the investigational treatment (maralixibat) is safe and effective in pediatric and adult participants who have cholestatic liver disease with pruritus that has been refractory to other therapies, and who have no other treatment options.
Gender:
ALL
Ages:
6 months and above
Trial Updated:
07/16/2025
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Cholestatic Liver Disease (except ALGS, PFIC, PBC and PSC)
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Recruiting
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: Site 22, Austin, Texas
Conditions: Head and Neck Squamous Cell Carcinoma
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Recruiting
Phase 1a/1b dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-330, determine the recommended Phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced or metastatic HER2-altered NSCLC. Phase 1a dose escalation is designed to assess the safety and tolerability of NVL-330 and to select the candidate RP2D(s) and, if applicable, the MTD. Phase 1b expansion is designed to further evaluate the overall safety and tolerability of the c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma
Recruiting
To learn about the possible effects of a prebiotic food-enriched diet (PreFED) targeting the gut microbiome in participants with melanoma who are starting immune checkpoint blockade (ICB) therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Unresectable Melanoma
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
Recruiting
Researchers are looking for new ways to treat people with high-risk muscle-invasive urothelial carcinoma (MIUC). Urothelial carcinoma is a type of bladder cancer that begins in cells that line the inside of the bladder and other parts of the urinary tract, such as part of the kidneys, ureters, and urethra. People with MIUC usually have chemotherapy before surgery, then surgery to remove the cancer. Chemotherapy is a type of medicine to destroy cancer cells or stop them from growing. After surger... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: UT Southwestern Medical Center ( Site 0103), Dallas, Texas
Conditions: Bladder Cancer
Assessing the Effects of Photobiomodulation on Clinical Recovery From Concussion in Adolescents
Recruiting
The purpose of this study is to compare effects of Photobiomodulation therapy (PBMt) to standard of care in adolescent athletes at risk for delayed recovery from subacute sports concussion, to substantiate the impact of subacute PBMt over time on functional and structural connectivity of the brain using advanced MRI sequences and to correlate the psychological and behavioral outcomes to neuroimaging findings
Gender:
ALL
Ages:
Between 13 years and 18 years
Trial Updated:
07/16/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Sports-related Concussion
Escitalopram in Asthma Patients With Frequent Exacerbation
Recruiting
Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), such as escitalopram are widely used for mood and anxiety disorders. However, they have also been explored, with promising findings, for a variety of disorders outside of psychiatry. Clinical studies of SSRIs in depressed people with asthma were associated with decreased asthma exacerbations and improvement in asthma control. In this study, the number of asthma exacerbations will be assessed as the primary outcome mea... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/16/2025
Locations: UT Southwestern, 1440 Empire Central, Ste. LD4.100, Dallas, Texas
Conditions: Asthma
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
Recruiting
The primary objective of the study is to investigate the safety and tolerability of ascending doses of GSK3862995B following single dose in healthy participants and repeat doses in participants with Chronic obstructive pulmonary disease (COPD).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/16/2025
Locations: GSK Investigational Site, Austin, Texas
Conditions: Pulmonary Disease, Chronic Obstructive
Tele-Collaborative Outreach to Rural Patients With Chronic Pain
Recruiting
This is a randomized controlled trial comparing the effectiveness of a remotely delivered collaborative care intervention for chronic pain versus a minimally enhanced control group. The specific aims of the study are: (1) compare the effectiveness of tele-collaborative pain care vs. minimally enhanced usual care to improve pain interference over 12 months of follow-up, and (2) oversample women and rural veterans of minoritized race/ethnicity to test heterogeneity of treatment effects across birt... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: VA North Texas Health Care System, Dallas, Texas
Conditions: Chronic Pain
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
Recruiting
The goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the HR+, HER2-low (immunohistochemistry \[IHC\]2+/in situ hybridization \[ISH\]- and IHC 1+) population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: Research Site 1101-0, Dallas, Texas
Conditions: Metastatic Breast Cancer
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients With Advanced Solid Tumors
Recruiting
This is a FIH, multicenter, open-label Phase I study to investigate the safety, tolerability, preliminary antitumor activity, as well as PK and pharmacodynamics of XL309 (previously ISM3091) administered alone or in combination with olaparib in subjects with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: Exelixis Clinical Site #4, Austin, Texas
Conditions: Advanced Solid Tumor